Диссертация (1146667), страница 21
Текст из файла (страница 21)
L., Romanuk T. N. // Plos ONE. —2012. —7. Режим доступа www.plosone.org149. Rodriguez-Palacios A., Ilic S., LeJeune J. T. Clostridium difficile withMoxifloxacin/Clindamycin Resistance in Vegetables in Ohio, USA, and PrevalenceMeta-Analysis [Электронный доступ] / Rodriguez-Palacios A., Ilic S., LeJeune J. //JournalofPathogens.—2014.Режимдоступаhttps://www.ncbi.nlm.nih.gov/pubmed/.150. Round J.L.
The Toll-like receptor 2 pathway establishes colonization by acommensal of the human microbiota/ Round J.L., Lee S.M., Li J. [et al.] // Science.— 2011. — Vol. 332. —P. 974–977.151. Rousseau. C. et al. Clostridium difficile colonization in early infancy isaccompanied by changes in intestinal microbiota composition // J Clin Microbiol. —2011.
— Vol. 49. —P. 858–865.152. Rubin, D.Rifaximin is effective for the treatment of Clostridiumdifficile-associated diarrhea: results of an open-label pilot study [Электронныйдоступ] / Rubin, D., Sohi, S., Glathar, M. [et al.] // Gastroenterol Res Pract. — 2011.Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/114153. Satta G. Persisting variation in testing and reporting Clostridium difficilecases / Satta G., Parekh S.
[et al.] //Journal of Infection Prevention. — 2015. — Vol.16, № 5. — P. 217–220.154. Schloss P.D. Status of the microbial census / Schloss P.D., HandelsmanJ.// Microbiol Mol Biol Rev. —2004. — Vol. 68. — P. 686–691.155. Seekatz A.M. Clostridium difficile and the microbiota / Seekatz A.M.,Young V.B. // J Clin Invest. — 2014. — Vol.
18. —P.1— 8.156. Semenyuk E. G. Spore Formation and Toxin Production in Clostridiumdifficile Biofilms [Электронный доступ]/ Semenyuk E. G., Laning M. L. [et al.] //Plos One. — 2014 . — Vol. 9. Режим доступа www.plosone.org157. Shanahan F.
The gut microbiota – a clinical perspective on lessonslearned // Nat Rev Gastroenterol Hepatol. —2012. — Vol. 9. — P. 609–614.158. Sheng, Y. H. Mucins in inflammatory bowel diseases and colorectalcancer / Sheng, Y. H., Hasnain, S. Z., Florin, T.
H. [et al.] // J. Gastroenterol.Hepatol. —2012. — Vol. 27. — P. 28–38.159. Shin J.H. Older Is Not Wiser, Immunologically Speaking: Effect of Agingon Host Response to Clostridium difficile Infections / Shin J.H., High K.P., WarrenC.A. // J Gerontol A Biol Sci Med Sci. —2016. — Vol. 71, № 7. —P. 916-922.160. Shrestha S.K. Acquisition of Clostridium difficile on Hands of HealthcarePersonnel Caring for Patients with Resolved C. difficile Infection / Shrestha S.K.,Sunkesula V.C., Kundrapu S. // Infect Control Hosp Epidemiol. —2016. — Vol. 37,№ 4. —P.
475-477.161. Shulman S.T. Theodor Escherich: the first pediatric infectious diseasesphysician? / Shulman S.T, Friedmann H.C, Sims R.H. // Clin Infect Dis. — 2007. —Vol. 45. —P. 1025–1029.115162. Skraban J. Gut microbiota patterns associated with colonization ofdifferent Clostridium difficile ribotypes [Электронный доступ] / Skraban J.,Dzeroski S. [et al.] // PLoS One. — 2013. — Vol.8. Режим доступаwww.plosone.org163. Stabler R.A. Macro and micro diversity of Clostridium difficile isolatesfrom diverse sources and geographical locations [Электронный доступ] / StablerR.A. [et al.] // PLoS One. — 2012. —Vol.7.
Режим доступа www.plosone.org164. Staley J.T. Measurement of in situ activities of nonphotosyntheticmicroorganisms in aquatic and terrestrial habitats / Staley J.T, Konopka A. // AnnuRev Microbiol . —1985. — Vol. 39. —P. 321–346.165. Stecher B. Mechanisms controlling pathogen colonization of the gut /Stecher B., Hardt W.D.
// Curr.Opin. Microbiol. — 2011. — Vol. 14, № 1. — P. 8291.166. Surawicz C. M. Guidelines for diagnosis, treatment, and prevention ofClostridium difficile infection / Surawicz C. M., Brandt L. J., Binion D. G. [et al.] //Am. J. Gastroenterol. — 2013. — Vol. 108, № 4. —P. 478 – 498.167. Swale A.
Calprotectin and Lactoferrin Faecal Levels in Patients withClostridium difficile Infection (CDI): A Prospective Cohort Study [Электронныйдоступ] / Swale A., Miyajima F., Paul Roberts [et al.] // PLOS ONE. — 2014. —Vol. 9. Режим доступа www.plosone.org.168. Tacconelli E. ESCMID guidelines for the management of the infectioncontrol measures to reduce transmission of multidrug-resistant Gram-negativebacteria in hospitalized patients / Tacconelli E., Cataldo M. A.
[et al.] // ClinMicrobiol Infect. —2014. — Vol. 20, № 1. — P. 1–55.169. Tailford L. E. Discovery of intramolecular trans-sialidases in human gutmicrobiota suggests novel mechanisms of mucosal adaptation [Электронный116доступ] / Tailford L. E., Owen C. D. [et al.] // Nature Communications. — Vol.2015. —6. Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/170. Tanaka T. A hidden pitfall in the preparation of agar media underminesmicroorganism cultivability/ Tanaka T., Kawasaki K. [et al.] // Appl EnvironMicrobiol. —2014. — Vol. 80, № 24.
— P. 7659-7666.171. Tenover F.C. Comparison of strain typing results for Clostridium difficileisolates from North America / Tenover F.C., Akerlund T., Gerding D.N. [et al.] // J.Clin. Microbiol. —2011. — Vol. 49, № 5. — P. 1831–1837.172. The NIH HMP Working Group. The NIH Human Microbiome Project //Genome Research.
— Vol. 19. —P. 2317–2323.173. Tian J.H. A novel fusion protein containing the receptor binding domainsof C. difficile toxin A and toxin B elicits protective immunity against lethal toxinand spore challenge in preclinical efficacy models / Tian J.H., Fuhrmann S.R. [et al.]// Vaccine. —2012.
— Vol. 30. —P. 4249–4258.174. Usui M. Genetic relatedness between Japanese and European isolates ofClostridium difficille originating from piglets and their risk associated with humanhealth [Электронный доступ] / Usui M., Nanbu Y. // Frontiers in microbiology. —2014. — Vol.
5. Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/175. Van Buul L.W. Antibiotic use and resistance in long term care facilities[Электронный доступ] / L.W. Van Buul, J.T. van der Steen [et al.] // J Am MedDir Assoc.—2012.—Vol.13 Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/176.
Vardakas K.Z. Treatment failure and recurrence of Clostridium difficileinfection following treatment with vancomycin or metronidazole: a systematicreview of the evidence / Vardakas K.Z., Polyzos K.A., Patouni K. [et al.] // Int JAntimicrob Agents. — 2012. — Vol. 40. —P. 1–8.117177. Vickery K. Presence of biofilm containing viable multiresistant organismsdespite terminal cleaning on clinical surfaces in an intensive care unit / Vickery K.,Deva A. [et al.] // Journal of Hospital Infection. — 2012. — Vol. 80. —P. 52-55.178.
Villano S.A. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficille strain M3, in healthy subjects / Villano S.A.,Seiberling M., Tatarowicz W. [et al.] // Antimicrob Agents Chemother. — 2012. —Vol. 56. — P. 5224–5229.179. Vindigni S. M.C.difficille Infection: Changing Epidemiology andManagement Paradigms [Электронный доступ] / Vindigni S.
M., Surawicz C. M.// Clinical and Translational Gastroenterology. — 2015. — Vol. 6. Режим доступаhttps://www.ncbi.nlm.nih.gov/pubmed/180. Vyas D. Fecal transplant policy and legislation / Vyas D., Aekka A., VyasA. // World J Gastroenterol. — 2015. — Vol. 21, № 1. —P. 6-11.181. Walker A.S., et al. Relationship between bacterial strain type, hostbiomarkers, and mortality in Clostridium difficile infection // Clin Infect Dis. —2013. — Vol. 56. —P. 1589–1600.182.
Wang P. Identification of Clostridium difficile Ribotype 027 for the FirstTime in Mainland China / Wang P., Zhou Y., Wang Z. [et al.] // Infect Control HospEpidemiol. —2014. — Vol. 35. — P. 95–98.183. Wang X. ICU-Onset Clostridium difficile Infection in a UniversityHospital in China: A Prospective Cohort Study [Электронный доступ] / Wang X.,Cai L., Yu R., et al.
// Plos One. — 2014. — 9. Режим доступа www.plosone.org.184. WenischJ.M.Hospital-acquiredClostridiumdifficileinfection:determinants for severe disease / Wenisch J.M., Schmid D., Kuo H.W. [et al.] // EurJ Clin Microbiol Infect Dis. — 2012. — Vol. 31. —P. 1923–1930.118185. Whitehead S.J. Is there any value in measuring faecal calprotectin inClostridium difficile positive faecal samples? / Whitehead S.J, Shipman K.E. [et al.]// J Med Microbiol. — 2014. — Vol. 63, № 4. —P. 590-593.186.
Wiegand P.N. Clinical and economic burden of Clostridium difficileinfection in Europe: a systematic review of healthcare-facility-acquired infection /Wiegand P.N., Nathwani D., Wilcox M.H. [et al.] // J Hosp Infect. — 2012. — Vol.81. —P. 1–14.187. Wilcox M. H. Overcoming barriers to effective recognition and diagnosisof Clostridium difficile infection // Clin Microbiol Infect. — 2012. — Vol. 18, № 6.—P. 13–20.188. Wopereis H. The first thousand days – intestinal microbiology of earlylife: establishing a symbiosis / Wopereis H., Oozeer R., Knipping K.
[et al.] //Pediatric Allergy and Immunology. —2014. — Vol. 25. — P. 428–438.189. Yakob L. Assessing control bundles for Clostridium difficile: a reviewand mathematical model [Электронный доступ] / Yakob L., Th. V. Riley [et al.]//EmergingMicrobesandInfections.—2014.—3.Режимдоступаhttps://www.ncbi.nlm.nih.gov/pubmed/190. Yan Q. Multilocus sequence typing (MLST) analysis of 104 Clostridiumdifficile strains isolated from China/ Yan Q., Zhang J., Chen C.
[et al.] // EpidemiolInfect. —2013. — Vol. 141. — P. 195–199.191. Yatsunenko T. Human gut microbiome viewed across age and geography/ Yatsunenko T., Rey F.E., Manary M.J. [et al.] // Nature. — 2012. — Vol. 486. —P. 222–227.192. Yun-Bo Chen. Molecular epidemiology of Clostridium difficile in atertiary hospital of China / Yun-Bo Chen., S.L. Gu, Wei Z.Q., Shen P., Kong H.S.[et al.] // J Med Microbiol. —2014. — Vol.
63. — P. 562–569.119193. Zahar J.R. Outcome of ICU patients with Clostridium difficile infection[Электронный доступ] / Zahar J.R., Schwebel C. [et al.] // Crit Care. —2012. —Vol. 16, № 6. Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/194. Zakharova N. / In-Patients with Clostridium difficile-associated diarrhea:identification of hypervirulent strain [Poster] / N. Zakharova, T. Fil // Poster session.— 23th UEG Week, October 2015, Barcelona, Spain.195.
Zhanel G.G. Fidaxomicin: A novel agent for the treatment of Clostridiumdifficile infection / Zhanel G.G., Walkty A.J., Karlowsky J.A. // Can J Infect DisMed Microbiol. —2015. — Vol. 26, № 6. — P. 305-312..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
